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Objectives.We sought to investigate the effects of mibefradil on
survival, hemodynamic variables and cardiac remodeling in a rat
model of chronic heart failure (HF) and to compare these effects
with those of the angiotensin-converting enzyme (ACE) inhibitor
cilazapril.
Background. The use of calcium channel blocking agents in
chronic HF has been disappointing. Most studies have shown that
these drugs have either no or even detrimental effects due in part
to the negative inotropic effects they induce. Mibefradil is a
calcium channel blocker that selectively blocks T channels and
displays moderately negative inotropic properties only at high
doses. Because T channels are upregulated in the hypertrophied
heart and could mediate hypertrophic signals and increase ar-
rhythmogenicity, blockade of these channels might be beneficial in
chronic HF.
Methods. Rats were subjected to coronary artery ligation and 9
months of treatment with mibefradil (15 mg/kg body weight per
day) or cilazapril (10 mg/kg per day) or no treatment. Survival
and systolic blood pressure were assessed over the 9-month
treatment period, after which cardiac hemodynamic variables and
structure were determined.
Results. Mibefradil increased survival rate to the same extent
as cilazapril (71% for mibefradil vs. 75% for cilazapril and 44% for
no treatment). Mibefradil decreased systolic blood pressure,
although to a lesser extent than cilazapril. Both treatments
decreased left ventricular (LV) end-diastolic and central venous
pressures, without any change in the first derivative of LV
pressure over time or heart rate. Mibefradil decreased LV weight
(although less than cilazapril) without affecting right ventricular
weight. Finally, both drugs normalized LV collagen density.
Conclusions. Mibefradil in a rat model improved survival to the
same extent as an ACE inhibitor, without impairing LV function, and
was associated with a reduction in LV weight and fibrosis. Thus,
mibefradil might be beneficial in the treatment of chronic HF.
(J Am Coll Cardiol 1997;29:416–21)
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Calcium antagonists are widely used in the treatment of
hypertension (1) and angina pectoris (2) because of their
vasorelaxing properties and their favorable effects on myocar-
dial oxygen supply and demand (3). However, their use in
chronic myocardial infarction has been disappointing, and
clinical studies have shown variable results (4–6). Calcium
channel antagonist use might be limited by the reflex increase
in sympathetic tone, especially in the case of dihydropyridines
(7,8), or their negative inotropic effects (9), which, in the case
of verapamil or diltiazem, are enhanced in the presence of left
ventricular (LV) dysfunction (10). In addition, the dihydropyr-
idine calcium channel blocking agent amlodipine seems to
have favorable effects on mortality only in patients with
nonischemic dilated cardiomyopathy (1).
Mibefradil (Ro 40-5967) is a new calcium channel blocker
that selectively blocks T-type calcium channels (11) and exerts
moderate negative inotropic effects at high doses only (9,12).
Indeed, in rats with chronic heart failure (HF), mibefradil
induces a dose-dependent decrease in arterial blood pressure
and increases coronary blood flow without any detectable
change in cardiac contractility (13). Furthermore, mibefradil
displays anti-ischemic properties similar to those of vera-
pamil (14,15), despite much more moderate effects on
cardiac function (15). This unique pharmacologic profile of
mibefradil might be of interest in the treatment of chronic
HF.
Recent experiments have also shown (16,17) that T-type
calcium channels mediate the responses to various hypertro-
phic signals. Thus, it is possible that they may represent a
trigger for the development of cardiac hypertrophy in various
pathophysiologic situations. Furthermore, cardiac hypertrophy
is associated with an increased T-channel activity in myocytes
(18–20). The presence of these channels in hypertrophied
hearts may make such hearts more prone to spontaneous
action potentials and increase arrhythmogenicity (18). Thus,
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blockade of these channels might have a beneficial effect on
cardiac hypertrophy and arrhythmias in pathologic situations
such as chronic HF.
Thus, the goals of our study were to investigate the effects
of the calcium channel blocker mibefradil on survival, systemic
and cardiac hemodynamic variables and cardiac structure in a
rat model of chronic HF and to compare these effects with
those of an angiotensin-converting enzyme (ACE) inhibitor.
Methods
Animals and treatment. Myocardial infarction was pro-
duced in 10-week old male Wistar rats by left coronary artery
ligation. For this purpose, animals were anesthetized with
50 mg/kg body weight of sodium methohexital intraperitone-
ally. The trachea was intubated, and the lungs were mechani-
cally ventilated with room air supplemented by low flow
oxygen. After a left thoracotomy, the proximal left coronary
artery was occluded by a suture to induce myocardial infarc-
tion. Sham-operated rats were subjected to the same protocol,
except that the snare was not tied. Fifteen minutes after
occlusion, the chest was closed in three layers (ribs, muscles
and skin). A plastic catheter connected to a 5-ml syringe was
placed in the chest before sewing and was used to remove air
from the chest after closure. The rats were allowed to recover
from anesthesia (usually within 15 min), after which they were
returned to their cages. The 24-h postoperative mortality rate
for this method was ;20% for the infarction group.
Seven days after ligation, infarcted rats were randomly
assigned to three treatment groups: no treatment (n 5 68) or
treatment with the calcium antagonist mibefradil (n 5 59,
15 mg/kg per day [Hoffmann-La Roche Ltd. Basel, Switzer-
land]) or the ACE inhibitor cilazapril (n 5 59, 10 mg/kg per
day [Hoffmann-La Roche]). Twenty sham-operated rats were
used as control animals. All treatments were given as food
admix in normal rat chow. Rats were weighed every week, and
their food intake was measured to allow adjustment of the drug
concentrations in the chow.
Study design. The survival study began 7 days after oper-
ation to exclude early mortality caused by the procedure or
acute myocardial infarction and was designed to last 9 months.
During the treatment period, cages were inspected daily for
dead animals. The body weight of the dead rats was recorded,
and the chest was opened to search for signs of cardiac rupture
or pulmonary infection. The heart was then removed, cleaned,
weighed and immersed in Bouin solution for subsequent
determination of infarct size.
Hemodynamic assessment. Systolic blood pressure (pleth-
ysmography) and heart rate were determined in conscious rats
just before the start of the treatment (i.e., 7 days after the
surgical procedure) and after 30, 90, 180 and 270 days of
treatment. After 270 days, the surviving rats were anesthetized
with thiopental (50 mg/kg intraperitoneally). The right carotid
artery and right external jugular vein were cannulated with 2F
micromanometer-tipped catheters (SPR 407, Millar Instru-
ments) that were advanced into the aorta and thoracic vena
cava, respectively, to record arterial and central venous pres-
sures. The aortic catheter was then advanced into the left
ventricle to record LV pressure and its maximal rate of
increase (dP/dt max). Rats were then killed by an overdose of
thiopental before removal of the heart.
Cardiac morphometry. Infarct size and cardiac collagen
density were measured in histologic sections by image analysis
as described previously (21). Infarct size was determined in all
rats (i.e., those spontaneously deceased and those killed after
9 months).
Measurement of plasma renin and plasma catecholamines.
Ten days before completion of the study, the surviving animals
were anesthetized with ether, and venous blood samples (1.25
ml) were collected in prechilled tubes containing EDTA (10
mmol/L final concentration). Tubes were immediately centri-
fuged at 3,000g for 8 min and stored at 2808C for determina-
tion of plasma renin activity (22) and catecholamine concen-
trations (high performance liquid chromatography).
Statistical analysis. All results, except survival, are given as
mean value 6 SEM. Survival curves were compared by the
log-rank test and the Mantel-Haenszel procedure (23). Inter-
group differences were evaluated by analysis of variance
(ANOVA) followed, if ANOVA revealed significant differ-
ences, by a Tukey test for multiple comparisons. Differences
were considered significant at p , 0.05.
Figure 1. Cumulative percent survival of rats with chronic HF, either
untreated (circles, n 5 68) or treated with mibefradil (15 mg/kg per
day [n 5 59; open triangles]) or cilazapril (10 mg/kg per day [n 5 59,
solid triangles]).
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ANOVA 5 analysis of variance
HF 5 heart failure
LV 5 left ventricular
LV dP/dt 5 first derivative of left ventricular pressure over time
RV 5 right ventricular
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Results
Survival. Figure 1 illustrates the survival curves for the
three treatment groups. Within the first 135 days, the rate of
death in the mibefradil and cilazapril groups was similar to that
of the untreated group. After 135 days, mortality was higher in
the untreated group than in either treatment group. After 9
months, the survival rate of the mibefradil (71%, p, 0.05) and
cilazapril groups (75%, p , 0.05) was significantly higher than
that of the untreated group (44%). The beneficial effect of
both treatments was also illustrated by the increase in mean
survival time from 200 days in the untreated group to 230 and
238 days in the mibefradil- and cilazapril-treated groups,
respectively.
Survival was also analyzed with regard to infarct size. In rats
with a moderate infarct (,40% of the left ventricle), both
mibefradil and cilazapril significantly improved the survival
rate at 9 months (no treatment 64%, mibefradil 92% [p ,
0.05], cilazapril 97% [p , 0.05]). In contrast, in animals with a
large infarct (.40% of the left ventricle), neither mibefradil
nor cilazapril improved the survival rate (no treatment 34%,
mibefradil 35%, cilazapril 39%).
Infarct size. Four rats (two untreated, one mibefradil
treated, one cilazapril treated) were excluded from the study
for an infarct size ,10% of the left ventricle. In addition,
determination of infarct size was not possible in two rats that
died, (one cilazapril treated, one mibefradil-treated), and they
were excluded from the study.
Infarct size in rats that died spontaneously and those killed
after 270 days was identical in both treatment groups (both
40 6 2%) and the untreated group (42 6 2%). Furthermore,
randomization resulted in a balanced distribution of infarct
sizes (Fig. 2).
Hemodynamic measurements in conscious rats. Figure 3
shows the evolution of systolic blood pressure and heart rate
determined in conscious surviving rats in the four different
groups during the 9-month study period. Seven days after
coronary artery ligation, systolic blood pressure in untreated
rats was significantly lower than that in sham-operated rats,
with no significant change in heart rate. Moreover, at this time
(i.e., immediately before the onset of treatment), systolic blood
pressure in the mibefradil- and cilazapril-treated groups was
similar and was not different from that in the untreated rats.
Compared with untreated rats, mibefradil induced a significant
decrease in systolic blood pressure after 30 treatment days
(29 mm Hg, p , 0.05). This effect was similar after 90
treatment days (27 mm Hg), after which it slightly increased
with time (215 and 229 mm Hg at 180 and 270 treatment
days, respectively). Mibefradil did not significantly modify
heart rate at any time.
Compared with the untreated group, the ACE inhibitor
cilazapril also decreased systolic blood pressure (230 mm Hg
at day 30, p , 0.05), and this effect persisted over time (230,
233 and 239 mm Hg at days 90, 180 and 270, respectively).
Furthermore, the decrease in systolic blood pressure induced
by cilazapril was always significantly more marked than that
induced by mibefradil. Cilazapril did not significantly modify
heart rate at any time.
Hemodynamic measurements in anesthetized rats. Table 1
summarizes cardiac hemodynamic variables and central ve-
nous pressure measured after 9 months in surviving anesthe-
tized animals. Compared with sham-operated animals, chronic
HF significantly decreased LV systolic pressure and LV dP/dt
max and significantly increased both LV end-diastolic and
central venous pressures. Compared with untreated rats, mi-
befradil reduced LV systolic pressure (220%, p , 0.05), LV
end-diastolic pressure (245%, p , 0.05) and central venous
pressure (222%, p , 0.05), without affecting LV dP/dt max.
Cilazapril also reduced LV systolic, LV end-diastolic and
central venous pressures without affecting LV dP/dt max.
Finally, all long-term hemodynamic changes induced by either
mibefradil or cilazapril were present both in moderate (,40%
of the LV) and large infarcts (.40% of the LV (Table 1).
Left ventricular morphology. Table 2 shows LV and right
ventricular (RV) weight and collagen density in the nonin-
Figure 2. Distribution of myocardial infarct size in rats with chronic
HF, either untreated (solid bars, solid line) or treated with mibefradil
(up-hatched bars, dashed line) or cilazapril (down-hatched bars,
dotted line).
Figure 3. Systolic blood pressure (left) and heart rate (right) mea-
sured in conscious sham-operated rats (open circles) or rats with
chronic HF, either untreated (solid circles) or treated with mibefradil
(open triangles) or cilazapril (solid triangles). *p , 0.05 versus
sham-operated rats. †p , 0.05 versus untreated rats with chronic HF.
‡p , 0.05 versus mibefradil-treated rats.
418 MULDER ET AL. JACC Vol. 29, No. 2
CALCIUM CHANNEL BLOCKADE AND SURVIVAL IN HF February 1997:416–21
farcted LV free wall in animals killed after 270 treatment days.
Compared with sham-operated rats, chronic HF increased LV
and RV weight and LV collagen density. Compared with
untreated rats, mibefradil moderately reduced LV weight and
more markedly decreased collagen density, without affecting
RV weight. Cilazapril markedly reduced LV and RV weight
and collagen density.
Renin and catecholamines. Table 2 shows plasma renin
activity and plasma norepinephrine and epinephrine concen-
trations determined in surviving animals. After 9 months,
chronic HF tended to increase plasma renin activity and
norepinephrine and epinephrine concentrations but not signif-
icantly. In mibefradil-treated rats, plasma renin activity was
increased, whereas norepinephrine and epinephrine levels
were not modified. Cilazapril markedly increased plasma renin
activity and reduced norepinephrine and epinephrine levels,
although the latter was not significant.
Discussion
The present study, performed in a rat model of chronic HF,
shows that long-term administration of the calcium channel
blocker mibefradil improved survival to the same extent as the
ACE inhibitor cilazapril. This improved survival was associated
with a reduction in both arterial and central venous pressures
and a normalization of LV end-diastolic pressure, with no sign
of negative inotropic effects. In addition, mibefradil moder-
ately decreased LV weight and normalized collagen density.
Survival and hemodynamic variables. The main finding of
this study is that the calcium channel blocker mibefradil
induced a marked increase in survival rate, close to that
induced by the ACE inhibitor cilazapril. This beneficial effect
differentiates mibefradil from other calcium channel blockers
that have been shown to have no or a detrimental effect on
survival in humans (1,5,24) or in experimental models of
chronic HF (25).
In the present study, only one calcium antagonist was
tested. In light of the major differences between the various
classes of calcium channel blockers, it would have been useful
to compare mibefradil with other, structurally unrelated cal-
cium channel blockers. However, our initial goal was to
investigate the effect of mibefradil itself. Because there was no
certainty as to study outcome, we considered it more reason-
able and practical to first test whether mibefradil was effica-
Table 1. Cardiac Hemodynamic Variables and Central Venous Pressure Determined in Anesthetized Rats After 9-Month Survival Study
Infarct Size
(% of LV)
LVSP
(mm Hg)
LVEDP
(mm Hg)
LV dP/dt max
(103 mm Hg/s)
CVP
(mm Hg)
Sham-operated rats 155 6 7 2.9 6 0.6 10.1 6 0.7 2.3 6 0.6
Rats with chronic HF
Untreated 31 6 2 139 6 5* 9.5 6 1.4* 6.9 6 0.4* 5.0 6 1.0*
Mibefradil 34 6 3 110 6 4*† 5.0 6 0.8† 6.1 6 0.3* 3.0 6 0.4†
Cilazapril 31 6 2 103 6 4*† 4.8 6 0.7† 5.6 6 0.2* 2.4 6 0.4†
Infarcts ,40%
Untreated 28 6 2 137 6 6* 9.4 6 1.5* 6.8 6 0.4* 5.0 6 1.2*
Mibefradil 30 6 1 111 6 4*† 4.9 6 0.9† 6.0 6 0.3* 2.9 6 0.4†
Cilazapril 28 6 2 104 6 4*† 4.0 6 0.6† 5.8 6 0.4* 2.3 6 0.5†
Infarcts .40%
Untreated 45 6 7 142 6 7* 11.9 6 2.5* 6.0 6 0.5* 4.9 6 1.3*
Mibefradil 46 6 2 109 6 7*† 5.2 6 2.0† 6.0 6 0.4* 3.2 6 1.5†
Cilazapril 45 6 3 99 6 9*† 6.2 6 1.5† 5.0 6 0.8* 2.7 6 1.0†
*p , 0.05 versus sham-operated rats. †p , 0.05 versus mibefradil. Data presented are mean value 6 SEM. CVP 5 central venous pressure; HF 5 heart failure;
LV dP/dt max5 first derivative of peak increase in left ventricular pressure; LVEDP5 left ventricular end-diastolic pressure; LVSP5 left ventricular systolic pressure.
Table 2. Plasma Renin Activity, Plasma Catecholamine Levels and Cardiac Morphology in Animals
Killed After 9 Months
Sham-Operated Rats
(n 5 7)
Rats With Chronic HF
Untreated
(n 5 26)
Mibefradil
(n 5 21)
Cilazapril
(n 5 22)
Renin (ng/ml per h) 29 6 9 71 6 18* 218 6 28*† 429 6 43*†‡
Norepinephrine (ng/ml) 1.87 6 0.02 2.45 6 0.21 2.17 6 0.18 1.61 6 0.13†
Epinephrine (ng/ml) 0.56 6 0.08 0.80 6 0.11 0.65 6 0.05 0.51 6 0.08
LV weight (g) 1.21 6 0.06 1.31 6 0.04* 1.24 6 0.03*† 1.01 6 0.03†‡
RV weight (g) 0.24 6 0.02 0.28 6 0.01* 0.27 6 0.01 0.23 6 0.01†‡
LV collagen density
(%)
2.02 6 0.23 3.33 6 0.19* 2.31 6 0.09† 2.24 6 0.14†
*p , 0.05 versus sham-operated rats. †p , 0.05 versus untreated rats. ‡p , 0.05 versus mibefradil-treated rats. Data
presented are mean value 6 SEM. RV 5 right ventricular; other abbreviations as in Table 1.
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cious in the present model before comparing it with other
calcium antagonists. Furthermore, comparison of different
drugs is difficult, not only with regard to which drugs to
compare, but also which doses to use in the comparison.
Ideally, comparisons between drugs require full dose–response
curves, which was not possible in the present model. Never-
theless, comparisons between mibefradil and other calcium
antagonists will require further investigation.
In our study, survival at 9 months was nearly identical in the
cilazapril- and mibefradil-treated groups. We limited the treat-
ment period to 9 months because of the high mortality rate
that has been observed in similar models after 9 months (21).
Had we used a longer treatment period we would have
performed the final hemodynamic and morphometric mea-
surements in only a small subgroup of rats with only moderate
cardiac dysfunction. Also, we wanted to compare mibefradil
with an ACE inhibitor, and this latter class of drugs has been
shown to improve survival after 9 months of treatment (21,26–
28). Thus, whether mortality may differ between mibefradil
and ACE inhibitor therapy .9 months is not known and
requires further investigation.
The hemodynamic effects of mibefradil, illustrated by the
significant and persistent hypotensive effect (although less
marked than that induced by the ACE inhibitor), probably
contributes to the improved survival. Indeed, ACE inhibitors
improve survival only when associated with a significant de-
crease in blood pressure (26). In the case of mibefradil, the
decrease in afterload is not associated with tachycardia but
possibly because of the direct effect of mibefradil on sinoatrial
conduction (29). Alternatively, this lack of tachycardia could
indicate that there is no activation of the sympathetic nervous
system secondary to vasodilation, in contrast to the observed
effects of dihydropyridine calcium channels blockers (7,30) or
hydralazine (31). The slight decrease in plasma norepinephrine
confirms the improvement in hemodynamic status without
sympathetic stimulation. Finally, the vasorelaxing properties of
mibefradil are apparently not associated with marked negative
inotropic effects, as suggested by the lack of effect on LV dP/dt
max. Such moderate negative inotropic effects have been
described in other experimental models of ischemia and
chronic HF (9,10,13,15) and contrast with the more marked
negative inotropic effects of other calcium antagonists, such as
diltiazem and verapamil (9,10,15).
Neurohumoral assessment. In the untreated rats with
chronic HF that survived for 9 months, we observed only slight
increases in plasma renin activity and plasma catecholamine
levels, possibly because rats with high activation of these two
systems died during the study. After 9 months, mibefradil-
treated rats had slightly increased plasma renin activity com-
pared with that in untreated rats, suggesting only moderate
activation of the circulating renin–angiotensin system. Again, it
is not possible to determine whether the increase in plasma
renin activity results from the direct effect of a calcium
antagonist or is due to the selection of rats with high plasma
renin levels, secondary to the marked effect on survival.
Nonetheless, this finding suggests that combined treatment
with mibefradil and drugs that interfere with the renin–
angiotensin system might have additive beneficial effects to
those of the calcium antagonist administered alone.
Left ventricular structure. Long-term treatment with mi-
befradil reduced LV weight as well as interstitial collagen
density in the noninfarcted LV. However, the effect of mibe-
fradil on LV ventricular weight was modest and much less
marked than that induced by the ACE inhibitor. Furthermore,
in contrast to the ACE inhibitor, mibefradil did not affect RV
weight. Thus, it is unlikely that the effect of mibefradil on
hypertrophy is the sole mechanism of the increased survival.
The effect of mibefradil on LV hypertrophy may be related
to the drug-induced decrease in afterload, which is probably
associated with a decrease in ventricular wall stress. These
hemodynamic changes may thus counteract the potentially
deleterious effects of the neurohumoral activation in chronic
HF (26,32). Alternatively, the decrease in LV weight might be
related to the role played by T-type calcium channels in the
development of myocyte hypertrophy. Indeed, T channels,
which are overexpressed in feline hypertrophied left ventricu-
lar myocytes (18) and cardiomyopathic hamster hearts (19),
have been shown to mediate calcium entry in response to
various mitogenic stimuli, such as angiotensin II (33),
endothelin-1 (16) or platelet-derived growth factor (17). In
addition, overexpression of T channels may make hypertro-
phied hearts more prone to spontaneous action potentials and
increase arrhythmogenicity in partially depolarized hypertro-
phied myocardium (18). Moreover, T channels are present at
the level of adrenal cells and may mediate aldosterone secre-
tion in response to potassium ions (34–36). Because aldoste-
rone has been shown (36) to have a major influence on the
development of cardiac fibrosis, it is possible that blockade of
these channels may indirectly affect fibrosis through decreased
aldosterone secretion. Thus, by directly preventing cardiac
hypertrophy or arrhythmias, or both, T-channel blockade by
mibefradil might contribute to the increased survival, indepen-
dent of the hemodynamic effects.
Long-term treatment with the calcium antagonist decreased
two indexes of cardiac preload: LV end-diastolic and central
venous pressure. This decrease in preload has not been
observed after short-term administration of mibefradil (13) or
after other calcium antagonists in similar models of chronic HF
(37,38). Despite a smaller effect on afterload, the effect of
mibefradil on preload was similar to that of the ACE inhibitor.
Thus, the beneficial effects of mibefradil on preload, which
were not observed after short-term administration, must be
partly related to a direct cardiac effect, independent of the
decrease in blood pressure. For example, the decrease in
myocardial collagen density with mibefradil could lead to
increased ventricular compliance and myocardial relaxation,
which could contribute to a direct effect on preload.
Conclusions. Our study in a rat model of chronic HF
showed that long-term treatment with the calcium antagonist
mibefradil improved survival to the same extent as an ACE
inhibitor. This improvement probably occurs as a result of the
effects of the drug on cardiac preload and afterload, as well as
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on cardiac hypertrophy and possibly on arrhythmias, in the
absence of marked negative inotropic properties. Our results
suggest that mibefradil might be beneficial in the treatment of
ischemic chronic HF.
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